700 related articles for article (PubMed ID: 31366280)
1. Current state of melanoma diagnosis and treatment.
Davis LE; Shalin SC; Tackett AJ
Cancer Biol Ther; 2019; 20(11):1366-1379. PubMed ID: 31366280
[TBL] [Abstract][Full Text] [Related]
2. Research progress in advanced melanoma.
Luo C; Shen J
Cancer Lett; 2017 Jul; 397():120-126. PubMed ID: 28385603
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapies for melanoma brain metastases: which drug for whom and when?
Ramanujam S; Schadendorf D; Long GV
Chin Clin Oncol; 2015 Jun; 4(2):25. PubMed ID: 26112811
[TBL] [Abstract][Full Text] [Related]
4. Pitfalls in the diagnosis of malignant melanoma: findings of a risk management panel study.
Troxel DB
Am J Surg Pathol; 2003 Sep; 27(9):1278-83. PubMed ID: 12960813
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs in cutaneous melanoma: Role as diagnostic and prognostic biomarkers.
Ross CL; Kaushik S; Valdes-Rodriguez R; Anvekar R
J Cell Physiol; 2018 Jul; 233(7):5133-5141. PubMed ID: 29226953
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in melanoma.
Griewank KG
Scand J Clin Lab Invest Suppl; 2016; 245():S104-12. PubMed ID: 27467728
[TBL] [Abstract][Full Text] [Related]
7. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
[TBL] [Abstract][Full Text] [Related]
8. The most common challenges in melanoma diagnosis and how to avoid them.
Marghoob AA; Changchien L; DeFazio J; Dessio WC; Malvehy J; Zalaudek I; Halpern AC; Scope A
Australas J Dermatol; 2009 Feb; 50(1):1-13; quiz 14-5. PubMed ID: 19178485
[TBL] [Abstract][Full Text] [Related]
9. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
10. New drug targets in metastatic melanoma.
Homet B; Ribas A
J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
[TBL] [Abstract][Full Text] [Related]
11. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.
Felix J; Cassinat B; Porcher R; Schlageter MH; Maubec E; Pages C; Baroudjian B; Homyrda L; Boukouaci W; Tamouza R; Bagot M; Caignard A; Toubert A; Lebbé C; Moins-Teisserenc H
Int Immunopharmacol; 2016 Nov; 40():466-473. PubMed ID: 27728898
[TBL] [Abstract][Full Text] [Related]
12. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy.
Moreira A; Leisgang W; Schuler G; Heinzerling L
Immunotherapy; 2017 Jan; 9(2):115-121. PubMed ID: 28128709
[TBL] [Abstract][Full Text] [Related]
13. Review of diagnostic, prognostic, and predictive biomarkers in melanoma.
Ankeny JS; Labadie B; Luke J; Hsueh E; Messina J; Zager JS
Clin Exp Metastasis; 2018 Aug; 35(5-6):487-493. PubMed ID: 29722000
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies for metastatic melanoma.
Chandra S; Pavlick AC
Dermatol Clin; 2012 Jul; 30(3):517-24. PubMed ID: 22800555
[TBL] [Abstract][Full Text] [Related]
15. Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.
Chapman PB; Hauschild A; Sondak VK
Am Soc Clin Oncol Educ Book; 2014; ():e412-21. PubMed ID: 24857132
[TBL] [Abstract][Full Text] [Related]
16. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
17. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
18. [Are immunological treatments beneficial for malignant melanoma of the skin?].
Vihinen P; Vuoristo MS; Hernberg M; Pyrhönen S
Duodecim; 2010; 126(14):1701-10. PubMed ID: 20804089
[TBL] [Abstract][Full Text] [Related]
19. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
20. From Breslow to BRAF and immunotherapy: evolving concepts in melanoma pathogenesis and disease progression and their implications for changing management over the last 50 years.
Rawson RV; Scolyer RA
Hum Pathol; 2020 Jan; 95():149-160. PubMed ID: 31704364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]